Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports a case where a patient with rheumatoid arthritis and alopecia areata saw significant improvement in both conditions after switching to daily upadacitinib treatment, specifically achieving complete hair regrowth within six months.

This study found that a single 2 ml injection of TEEV every 4 weeks offers similar beneficial effects with fewer side effects compared to injecting the same dose every 2 weeks in postmenopausal women.

This study suggests that BRAF inhibitors, particularly Encorafenib and Dabrafenib, may have potential applications in wound healing by targeting specific proteins involved in the healing process in murine models.

This study noted that combining oral acitretin with narrowband ultraviolet B therapy may reduce treatment time and dosages for psoriasis, potentially lowering the long-term skin cancer risk.

This letter discusses the potential of the Janus kinase 1 inhibitor abrocitinib for treating oral lichen planus but provides no new research findings.

In this case study, a 12-year-old girl with severe Crohn colitis achieved impressive clinical and endoscopic remission after receiving infliximab and azathioprine as first-line treatment, suggesting potential benefits of early intensive therapy.

This review found that fulvestrant is well tolerated in postmenopausal women with hormone receptor-positive advanced breast cancer, showing lower incidence of joint disorders than non-steroidal aromatase inhibitors.

This study found no significant difference in the seroconversion rate of SARS-CoV2 IgG between patients with Immune Mediated Inflammatory diseases undergoing Targeted Immune-Modulating Therapies and those on conventional systemic treatment.

This study suggests that the InlB321/15 protein may accelerate wound healing by increasing cell proliferation and reducing wound closure time in both cell culture and mouse models.

This study reports that a patient with subacute cutaneous lupus erythematosus experienced disease exacerbation after the first dose of the BNT162b2 mRNA COVID-19 vaccine, but tolerated the second dose without adverse reactions.

This case study reports that a 15-year-old male with multiple autoimmune conditions showed significant improvement in skin and gastrointestinal symptoms, along with hair regrowth, after 16 weeks of treatment with the JAK-1 inhibitor upadacitinib, demonstrating its potential in managing complex autoimmune disorders.

This review outlines the genetic basis of GABEB, highlighting reduced type XVII collagen as a distinguishing marker from Herlitz JEB, and discusses potential therapeutic avenues without presenting new results.

This study found that NIMP-R14-conjugated nanoparticles, loaded with roflumilast, effectively targeted neutrophils to reduce inflammation and improve symptoms in a mouse model of psoriasiform dermatitis, suggesting potential for targeted therapy in autoimmune skin diseases.

This article reviews numerous drug reactions and interactions for various medications and does not present new research findings.

This article discusses common skin side effects of EGFR inhibitors like cetuximab, noting their management remains based on clinical experience without strict therapy protocols, but provides no new clinical findings.

Ebastine may help regrow hair in alopecia areata patients.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

Tocilizumab might be an effective treatment for COVID-19.

In this case study, treatment with the selective JAK1 inhibitor upadacitinib significantly improved symptoms in a patient with refractory alopecia areata, vitiligo, ankylosing spondylitis, and allergic asthma-nasal syndrome, though a transient liver function abnormality was noted.

In this study, a strong positive correlation was found between clinician-reported and patient-reported measures for assessing eyebrow and eyelash hair loss in patients with severe alopecia areata, indicating high agreement during treatment with baricitinib over 52 weeks.

Bempikibart may help regrow hair in people with alopecia areata.

In this retrospective study, baricitinib and ritlecitinib showed similar effectiveness and safety over 52 weeks for treating severe alopecia areata, with non-severe adverse events more common for baricitinib, driven by weight gain.

In this study, researchers found that the JAK1/2 inhibitor ruxolitinib helped normalize tissue-specific autoimmunity in APECED patients by reducing inflammation and immune cell accumulation, but it was also linked to subclinical side effects like anemia and weight gain.

In this randomized study, BAY 1158061, a prolactin receptor antibody, was found to be safe, well-tolerated, and exhibited low immunogenicity in healthy postmenopausal women, but had no effect on serum prolactin levels compared to placebo.

This study found extensive real-world and clinical trial exposure to baricitinib across various disease states, ages, and racial populations, contributing data to its overall profile.

In two phase 3 clinical trials, this study found that adults with severe alopecia areata receiving baricitinib experienced significant hair regrowth on the scalp, eyebrows, and eyelashes over 36 weeks compared to placebo, although longer-term data are needed to fully assess benefits and risks.

This source does not report specific results but compiles information on recent advancements in Advanced Therapy Medicinal Products and regenerative medicine from non-academic sources as of March 2026.

In this case study, a 13-year-old girl with multiple autoimmune symptoms was successfully treated with the antibiotic and immunomodulatory drug co-trimoxazole.